Literature DB >> 25625000

From minimal to maximal surgery in the treatment of hepatocarcinoma: A review.

Marcos Vinicius Perini1, Graham Starkey1, Michael A Fink1, Ramesh Bhandari1, Vijayaragavan Muralidharan1, Robert Jones1, Christopher Christophi1.   

Abstract

Hepatocellular carcinoma represents one of the most challenging frontiers in liver surgery. Surgeons have to face a broad spectrum of aspects, from the underlying liver disease to the new surgical techniques. Safe liver resection can be performed in patients with portal hypertension and well-compensated liver function with a 5-year survival rate of 50%, offering good long-terms results in selected patients. With the advances in laparoscopic surgery, major liver resections can be performed with minimal harm, avoiding the wound and leak complications related to the laparotomies. Studies have shown that oncological margins are the same as in open surgery. In patients submitted to liver resection (either laparoscopic or open) who experience recurrence, re-resection or salvage liver transplantation has been showing to be an alternative approach in well selected cases. The decision making approach to the cirrhotic patient is becoming more complex and should involve hepatologists, liver surgeons, radiologists and oncologists. Better understanding of the different risk factors for recurrence and survival should be aimed in these multidisciplinary discussions. We here in discuss the hot topics related to surgical risk factors regarding the surgical treatment of hepatocellular carcinoma: anatomical resection, margin status, macrovascular tumor invasion, the place of laparoscopy, salvage liver transplantation and liver transplantation.

Entities:  

Keywords:  Cirrhosis; Hepatectomy; Hepatocellular carcinoma; Liver resection; Liver transplantation; Survival

Year:  2015        PMID: 25625000      PMCID: PMC4295198          DOI: 10.4254/wjh.v7.i1.93

Source DB:  PubMed          Journal:  World J Hepatol


  81 in total

1.  High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation.

Authors:  Margarita Sala; Josep Fuster; Josep M Llovet; Miquel Navasa; Manel Solé; María Varela; Fernando Pons; Antoni Rimola; Juan Carlos García-Valdecasas; Concepció Brú; Jordi Bruix
Journal:  Liver Transpl       Date:  2004-10       Impact factor: 5.799

Review 2.  Current strategy for staging and treatment: the BCLC update and future prospects.

Authors:  Alejandro Forner; María E Reig; Carlos Rodriguez de Lope; Jordi Bruix
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

3.  Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Authors:  J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

4.  Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria.

Authors:  Kheng Choon Lim; Vivian W Wang; Fahad J Siddiqui; Luming Shi; Edwin S Y Chan; Hong Choon Oh; Say Beng Tan; Pierce K H Chow
Journal:  Hepatology       Date:  2014-05-29       Impact factor: 17.425

5.  Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma.

Authors:  J I Herrero; B Sangro; J Quiroga; F Pardo; M Herraiz; J A Cienfuegos; J Prieto
Journal:  Liver Transpl       Date:  2001-07       Impact factor: 5.799

6.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

Review 7.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

Review 8.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

Review 9.  Surgical treatment of hepatocellular carcinoma: similar long-term results despite geographic variations.

Authors:  Timothy M Pawlik; Nestor F Esnaola; Jean-Nicolas Vauthey
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

10.  The international position on laparoscopic liver surgery: The Louisville Statement, 2008.

Authors:  Joseph F Buell; Daniel Cherqui; David A Geller; Nicholas O'Rourke; David Iannitti; Ibrahim Dagher; Alan J Koffron; Mark Thomas; Brice Gayet; Ho Seong Han; Go Wakabayashi; Giulio Belli; Hironori Kaneko; Chen-Guo Ker; Olivier Scatton; Alexis Laurent; Eddie K Abdalla; Prosanto Chaudhury; Erik Dutson; Clark Gamblin; Michael D'Angelica; David Nagorney; Giuliano Testa; Daniel Labow; Derrik Manas; Ronnie T Poon; Heidi Nelson; Robert Martin; Bryan Clary; Wright C Pinson; John Martinie; Jean-Nicolas Vauthey; Robert Goldstein; Sasan Roayaie; David Barlet; Joseph Espat; Michael Abecassis; Myrddin Rees; Yuman Fong; Kelly M McMasters; Christoph Broelsch; Ron Busuttil; Jacques Belghiti; Steven Strasberg; Ravi S Chari
Journal:  Ann Surg       Date:  2009-11       Impact factor: 12.969

View more
  4 in total

1.  915-MHz microwave-assisted laparoscopic hepatectomy: a new technique for liver resection.

Authors:  Xiaogang Dong; Zhongquan Sun; Tianchun Wu; Wenjia Guo; Sheng Yan; Shusen Zheng
Journal:  Surg Endosc       Date:  2018-10-29       Impact factor: 4.584

Review 2.  Laparoscopic liver resection: Experience based guidelines.

Authors:  Fabricio Ferreira Coelho; Jaime Arthur Pirola Kruger; Gilton Marques Fonseca; Raphael Leonardo Cunha Araújo; Vagner Birk Jeismann; Marcos Vinícius Perini; Renato Micelli Lupinacci; Ivan Cecconello; Paulo Herman
Journal:  World J Gastrointest Surg       Date:  2016-01-27

3.  Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients.

Authors:  Bei-Ge Jiang; Neng Wang; Jian Huang; Yuan Yang; Liang-Liang Sun; Ze-Ya Pan; Wei-Ping Zhou
Journal:  Oncotarget       Date:  2017-04-25

4.  Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells.

Authors:  Wei Gao; Heungnam Kim; Mitchell Ho
Journal:  PLoS One       Date:  2015-09-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.